TSX closed
Loading markets…

Advertisement

Stocks

Why Voyageur Pharmaceuticals Ltd stock is rising today

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:VM.V

Follow VM

Photos provided by Pexels

Voyageur Pharmaceuticals Ltd (VM.V) is making waves on the TSX Venture Exchange with a notable 4.76% increase in stock price today, driven by strategic advancements in its iodine production projects.

In the latest trading session, Voyageur Pharmaceuticals Ltd experienced a significant uptick, closing at CA$0.11, reflecting a 4.76% rise. This surge can be attributed to the company's recent engagement with Fluor Corporation to advance feasibility studies for its iodine production and integrated contrast drug manufacturing facility.

Advertisement

Voyageur Pharmaceuticals Ltd

VM.V

Full stock page →

VM.V

Voyageur Pharmaceuticals Ltd

Source:WealthAwesomeWealthAwesome
↑ $0.01 (13.64%)
120 day period
$0.08$0.13$0.17Apr 15Jul 13Oct 6

Market cap

$28.29M

52W high

$0.20

52W low

$0.07

1W change

-10.71%

Beta

0.46

Analyst Price Targets

Based on analyst covering VM · as of Sep 17, 2026

📈

Wall Street analysts forecast VM stock price to rise 340.0% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$0.55

+340.0% Upside

Current Price

C$0.13

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on VM's historical volatility

HistoricalForecast68%95%
C$0.06C$0.09C$0.12C$0.16C$0.19C$0.22TodayMay 28Aug 4Oct 6Nov 18Jan 1Feb 13

30-Day Vol

55.3%

Annualized

90-Day Vol

84.8%

Annualized

Trend (90d)

-32.3%

Annualized drift

90d Mean

C$0.11

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.12C$0.10 – C$0.15
60 trading daysC$0.12C$0.09 – C$0.15
90 trading daysC$0.11C$0.08 – C$0.15

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should consider the implications of Voyageur's strategic partnerships and its potential to disrupt the medical imaging market with a fully integrated supply chain for contrast agents.

4.76% Surge in Stock Price

Voyageur Pharmaceuticals Ltd's stock rose to CA$0.11, reflecting investor optimism following the announcement of significant feasibility studies.

Bull case

The partnership with Fluor Corporation boosts Voyageur's credibility and operational capabilities. This positions the company to lead in the North American contrast media market, which could result in increased revenues and market share.

Bear case

Despite the positive news, Voyageur's current market cap of CA$19.74 million and lack of profitability raise concerns about the company's ability to execute its ambitious plans and navigate potential regulatory hurdles.

Advertisement

Strategic Partnership with Fluor Corporation

Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct feasibility studies for two pivotal projects aimed at enhancing its supply chain for radiology contrast drugs. This collaboration is expected to streamline the production of high-purity iodine and barium contrast media, which are essential for medical imaging.

Market Position and Future Prospects

With a focus on becoming North America's first fully integrated producer of barium and iodine contrast agents, Voyageur is setting itself apart in a competitive market. The feasibility studies are a crucial step in achieving this goal, potentially leading to significant revenue growth and a stronger market presence.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: June 25, 2026
Last Updated: June 25, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement